A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Glycopyrrolate; Indacaterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms EXPEDITION; FLIGHT-2
- Sponsors Novartis Pharmaceuticals
- 19 Jul 2019 Results of this post-hoc analysis of pooled data from the replicate FLIGHT1 and FLIGHT2 studies compared the efficacy and safety of IND/GLY with that of IND, GLY, and placebo in patients with moderate-to-severe COPDpublished in the Respiratory Medicine
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
- 23 May 2018 Results of pooled analysis of the FLIGHT1 and FLIGHT2 studies assessing impact of reversibility on lung function, health status, and dyspnea in COPD patients presented at the 114th International Conference of the American Thoracic Society